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ABSTRACT
Clinically nonfunctioning pituitary adenomas (NFPA) are the most common pituitary tumors after 
prolactinomas. The absence of clinical symptoms of hormonal hypersecretion can contribute to the 
late diagnosis of the disease. Thus, the majority of patients seek medical attention for signs and 
symptoms resulting from mass effect, such as neuro-ophthalmologic symptoms and hypopituitarism. 
Other presentations include pituitary apoplexy or an incidental finding on imaging studies. Mass effect 
and hypopituitarism impose high morbidity and mortality. However, early diagnosis and effective 
treatment minimizes morbidity and mortality. In this publication, the goal of the Neuroendocrinology 
Department of the Brazilian Society of Endocrinology and Metabolism is to provide a review of the 
diagnosis and treatment of patients with NFPA, emphasizing that the treatment should be performed 
in reference centers. This review is based on data published in the literature and the authors’ 
experience. Arch Endocrinol Metab. 2016;60(4):374-90
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INTRODUCTION
A denomas represent the most common primary neoplasm of the anterior pituitary, constituting 
10-15% of all intracranial tumors (1). They are benign 
neoplasms of monoclonal origin, and their pathoge nesis 
is thought to involve mostly inactivating mutations 
in tumor suppressor genes or activating mutations 
in proto-oncogenes, although the specific mutations 
remain to be identified in most cases (2).
Pituitary adenomas are divided into functioning 
and non-functioning according to the presence or 
absence of clinical syndromes resulting from hormonal 
hypersecretion. Upon imaging, these tumors can 
be further classified as microadenomas (< 10 mm) 
or macroadenomas (≥ 10 mm) according to size. 
Approximately 30% of pituitary adenomas are clinically 
nonfunctioning, and the majority of patients seeks 
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from mass effect on surrounding structures, i.e., 
the optic chiasm, cranial nerves and pituitary stalk. 
However, some cases may be diagnosed incidentally 
through imaging studies performed for other purposes 
(3). In this statement, the authors will provide a 
review on the diagnosis and treatment of patients with 
nonfunctioning pituitary adenomas (NFPA) whose 
presentation was not incidental.
The precise prevalence of NFPA is difficult to define 
because many patients are asymptomatic. The prevalence 
of clinically manifest NFPA is estimated at 7-22 cases per 
100,000 inhabitants (4,5); its estimated incidence is 1 case 
per 100,000 inhabitants/year (6), with a peak incidence 
between the fourth and sixth decades of life with no 
sex predilection (7). Thus, it is estimated that there are 
approximately 2,000 new cases of NFPA diagnosed annually 
in Brazil (base for calculation: 200 million inhabitants).
The definition of NFPA is essentially clinical until 
histopathological analysis is performed, i.e., benign pituitary 
tumors that are not associated with clinical manifestations 
of hypersecretion of pituitary hormones (3). Most of these 
tumors are capable of producing glycoprotein hormones 
or their subunits in sufficient quantities to be detected 
by immunohistochemistry (IHC), in situ hybridization 
or molecular biology techniques; however, they cannot 
secrete detectable amounts of glycoprotein hormones in 
the circulation or secrete biologically inactive forms (8-
14). Nevertheless, the α subunit of glycoprotein hormones 
may be elevated in the circulation in approximately 30% 
of NFPA patients (15). Although most of the gonado-
troph adenomas are hormonally silent, rarely they secrete 
gonadotropin and may produce specific endocrine 
syndromes, such as ovarian stimulation-like syndrome in 
pre-menopausal women (16,17).
NFPA represents a heterogeneous group of adenomas 
and may be classified as gonadotropinomas, silent tumors that 
express only one pituitary hormone [adrenocorticotropin 
hormone (ACTH); thyroid-stimulating hormone 
(TSH), prolactin and growth hormone (GH)], multiple 
pituitary hormones (silent adenoma subtype 3) or no 
hormone (null cell) based on hormone expression on 
immunohistochemical examination. Most NFPA stems 
from gonadotropic cells, with immunostaining for follicle-
stimulating hormone (FSH), luteinizing hormone (LH) 
and/or alpha subunit of glycoprotein hormones (14). 
Among silent corticotropinomas, silent adenoma subtype 
1 (densely granulated) and subtype 2 (sparsely granulated) 
can be found (8,13,14). Table 1 shows the pathological 
classification of NFPA.
As to the importance of the characterization 
of NFPA in relation to the expression of pituitary 
hormones, some studies have found a relationship 
between the expression of hormones by IHC and 
tumor aggressiveness. In a study of 213 patients with 
NFPA, Yamada and cols. (18) found cavernous sinus 
invasion in 83% of silent corticotropinomas, 67% of 
adenomas subtype 3, 38% of null cell adenomas and 
11% of gonadotropinomas, demonstrating differences 
in tumor invasiveness among NFPA subtypes.
In this publication, the goal of the Neuroendocrinology 
Department of the Brazilian Society of Endocrinology 
and Metabolism is to provide a review on the diagnosis 
and treatment of patients with NFPA, emphasizing that 
the treatment should be performed in reference centers. 
Thus, based on data published in the literature and the 
experience of the authors, representatives of the main 
reference centers for the treatment of pituitary adenomas 
in Brazil, we present a review for the diagnosis, treatment 
and follow-up of this disease.
DIAGNOSIS
Clinical presentation
The absence of clinical symptoms of hormonal 
hypersecretion contributes to the late diagnosis of the 
disease. Thus, the majority of patients seeks medical 
attention for signs and symptoms resulting from mass effect 
produced by a macroadenoma. NFPA can be manifested 
by symptoms of compression of the tumor on the normal 
gland and/or on the surrounding structures to the pituitary 
gland, such as the optic chiasm, cranial nerves, or pituitary 
stalk, causing hypopituitarism, hyperprolactinemia or, less 
frequently, pituitary apoplexy. Additionally, some cases 
may be diagnosed incidentally through imaging studies 
Table 1. Pathological classification of clinically nonfunctioning pituitary 
adenomas
Tumor subtype Hormone expression Frequency











Null cell None 27%
Silent adenoma type 3 Multiple pituitary hormones <1%
FSH: follicle-stimulating hormone; LH: luteinizing hormone; GH: growth hormone; 
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performed for other purposes, such as the evaluation of 
traumatic brain injury (12,19). The forms of clinical 
presentation of NFPA are found in Chart 1.
Chart 1. Forms of presentation of clinically nonfunctioning pituitary 
adenomas
• Mass effect (neuro-ophthalmologic complaints, neurologic, hypopituitarism 
and hyperprolactinemia by stalk effect)
• Pituitary apoplexy
• Incidental finding (pituitary incidentaloma)
NFPA with suprasellar expansion can reach and 
cause compression of the optic chiasm, determining 
varied visual impairment according to the involvement 
of nerve fibers. The most classic change is bitemporal 
hemianopia, but the visual loss can be uni-, bilateral or 
even central and is usually asymmetric and insidious. 
These visual changes can be detected by confrontation 
visual field testing or by visual field perimetry, preferably 
manual (Goldmann) (20). The suprasellar extension 
can produce headaches or, more rarely, intracranial 
hypertension, as large tumors may obstruct the foramen 
of Monro, leading to hydrocephalus (21). Headaches 
may be related to various factors, such as increased intra-
sellar pressure, peritumoral inflammatory reaction, in 
addition to release of local neurotransmitters (22,23).
The invasion of the cavernous sinus (parasellar 
expansion) may affect the cranial nerves, causing a 
varied clinical profile according to the compromised 
nerve: eyeball shift out and/or ptosis (III nerve lesion, 
oculomotor nerve), deviation of the eyeball superiorly 
and slightly inward (IV nerve involvement, trochlear 
nerve) and convergent strabismus (lesion VI nerve, 
abducens nerve). More rarely, trigeminal neuralgia 
(lesion of branches V1 and/or V2 of V nerve, the 
trigeminal nerve) may occur (24).
More rarely, the tumor may be very aggressive and 
compress other intracranial structures, resulting in 
symptoms such as temporal lobe epilepsy or hydrocephalus. 
Cerebrospinal fluid (CSF) rhinorrhea can occur if the 
tumor causes erosion to the sellar floor and extends 
inferiorly (infrasellar extension) to the sphenoid sinus (12).
The deficiency of at least one pituitary hormone is 
generally present in most patients with macroadenoma 
and results from the compression of the normal anterior 
pituitary and/or pituitary stalk, preventing the stimulation 
of pituitary cells by hypothalamic factors and thus affecting 
the secretion of pituitary hormones. Hypogonadism, one 
of the most common deficiencies, can result from either a 
compressive effect on gonadotropic cells or the pituitary 
stalk or by non-tumoral hyperprolactinemia. In patients 
with NFPA, hyperprolactinemia occurs by compression 
of the pituitary stalk, which prevents the arrival of 
dopamine to the anterior pituitary, the main inhibitor 
of prolactin secretion, characterizing the hypothalamic-
pituitary disconnection (stalk effect) (25-28).
Apoplexy is an acute vascular event that presents 
with acute expansion of tumor volume, manifesting 
itself by sudden onset of intense headache. It may 
be associated with neuro-ophthalmologic signs and 
symptoms, intracranial hypertension and altered 
levels of consciousness. In addition, it can cause 
hypopituitarism, including adrenal insufficiency, which 
can exacerbate the patient’s clinical status. The real risk 
of apoplexy in NFPA is not known because most of the 
cases reported the apoplexy was the clinical picture that 
led to the diagnosis of NFPA (29). Apoplexy is reported 
in 4-10% of cases in surgical series (25,27,28). As 
described in a review article (30), follow-up studies of 
patients with the incidental finding of nonfunctioning 
lesions likely to be NFPA reported an incidence of 
apoplexy in macroadenomas of 1.1% per year.
Currently, due to the increased availability of 
cranial computerized tomography (CT) and magnetic 
resonance imaging (MRI) in investigations of several 
neurologic disorders, there have been an increasing 
number of NFPA diagnoses in asymptomatic patients or 
those without signs suggesting pituitary pathology. In 
this situation, the NFPA is called an incidentaloma, which 
represents approximately 10% of clinical presentations 
among patients with NFPA (1,25,27,31,32).
Table 2 summarizes the main clinical and laboratory 
characteristics of patients with NFPA evaluated in large 
studies (25-28). Growth hormone deficiency was not 
systematically assessed in most series; however, one study 
showed somatotrophic deficiency in 77% of cases (33).
Table 2. Clinical and laboratory characteristics of patients with clinically 
nonfunctioning pituitary adenoma
Clinical characteristics Frequency
Headache 10 – 41%
Visual impairment 31 – 68%
Alteration of cranial nerve 4 – 5%
Incidental finding 7 – 12%
Hyperprolactinemia 28 – 54%
Apoplexy 4 – 10%
Hypopituitarism – documented 62 – 85%
Hypogonadism 43 – 78%
Hypocortisolism 24 – 32%
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Supplementary tests and differential diagnosis
NFPA diagnosis is based on the presence of sellar mass 
identified by CT, or preferably, MRI of the sella turcica, 
in the absence of signs and/or clinical symptoms of 
hormonal hypersecretion.
After the diagnosis of sellar mass, it is necessary to 
assess pituitary function with regard to hypersecretion 
or hypopituitarism. In the case of NFPA, the absence 
of hormone hypersecretion should be based on clinical 
evaluation and laboratory test analysis through the 
measurement of insulin-like growth factor type I 
(IGF-I) and prolactin (34,35). Tests for screening 
hypercortisolism include overnight 1-mg dexamethasone 
suppression test, Liddle 1 (suppression with low dose 
dexamethasone – 0.5 mg every 6 hours for 48 hours), 
late-evening salivary cortisol and urinary free cortisol. 
These tests are indicated only for patients in whom there 
is a clinical suspicion of Cushing’s disease (12,36).
The hook effect, an artifact of the dosage of the 
prolactin assay, occurs when excessively high levels of this 
hormone interfere with the formation of the complex 
antibody-antigen-antibody sandwich (immunometric 
method). The final effect is the detection of a signal lower 
than that expected by the test, erroneously determining a 
lower level of prolactin. To avoid this problem, prolactin 
assessment must be repeated at a serum dilution of 1:100. 
If the pituitary adenoma is a prolactinoma, prolactin levels 
will dramatically increase (proportional to tumor size). 
However, if the sellar lesion is not a prolactinoma, but 
an NFPA (or other sellar lesion), prolactin levels remain 
at a similar level after dilution (hyperprolactinemia due 
to hypothalamic-pituitary disconnection). Modestly 
elevated levels of prolactin (usually not exceeding 150-
200 ng/mL) may occur in patients with macroadenomas 
or other sellar lesions by loss of inhibitory tone due to 
disruption of dopamine input on lactotrophs, configuring 
the stalk effect or hypothalamic – pituitary disconnection. 
Thus, in patients with macroadenoma, especially those 
> 3 cm and with normal or not so elevated prolactin 
values, a new dosage after a prolactin serum dilution 
of 1:100 must be obligatorily performed to distinguish 
prolactinoma from NFPA (34,37,38).
Cystic prolactinomas constitute another potential 
cause of discrepancy between the prolactin serum level and 
tumor volume since, although the tumor volume is large, 
the number of viable cells is low due to cystic degeneration.
NFPA, especially macroadenomas, can determine 
impairment of pituitary function by the involvement 
of gland or pituitary stalk compression; thus, hormone 
deficiencies should be investigated regardless of 
symptoms (35). The risk of hypopituitarism is 
directly related to tumor size; therefore, laboratory 
investigations should be performed in all patients with 
nonfunctioning macroadenomas. In patients with 
nonfunctioning microadenomas, the evaluation of 
pituitary function is suggested for lesions between 6-9 
mm because these appear to be more closely associated 
with hypopituitarism (35). The assessment of pituitary 
function should be performed by the following 
hormonal dosages: 1) Corticotrophic axis through 
baseline cortisol levels (between 7:00am and 9:00 am) 
or stimulation test (synthetic ACTH or insulin tolerance 
test). Baseline cortisol levels < 3 mg/dL confirm adrenal 
insufficiency, while levels > 18 mg/dL exclude it. Cortisol 
values between 3-18 mg/dL require a stimulation test. 
Cortisol levels > 18 mg/dL during the stimulation 
test exclude the diagnosis of adrenal insufficiency [for 
details on the diagnosis of adrenal insufficiency see 
reference #(39)]; 2) Thyrotrophic axis through TSH 
and free T4 measurements. Although the TSH level is 
not informative in cases of central hypothyroidism (may 
be low, inappropriately normal or slightly elevated), a 
frankly high level indicates primary hypothyroidism, 
especially if accompanied by antithyroid autoantibodies; 
3) Gonadotropin axis by measuring levels of LH, FSH 
and, in men, testosterone. In women, the determination 
of gonadotropin levels and menstrual cycles is sufficient 
for the evaluation of gonadal function. Inappropriately 
normal or low levels of gonadotropins in menopausal 
women indicate hypopituitarism (gonadotropin 
deficiency); and 4) Somatotrophic axis through IGF-I 
measurement. Importantly, normal IGF-I levels in adults 
with pituitary adenoma do not exclude the diagnosis of 
GH deficiency because nearly half of adult patients with 
GH deficiency may have normal levels of IGF-I (40). 
Nevertheless, in the presence of three pituitary hormone 
deficiencies, low IGF-I values are specific predictors of 
GH deficiency (41,42). If at least three deficiencies do 
not occur, GH liberation testing should be performed. 
Additionally, IGF-I levels may be low due to diseases, 
such as hepatic or renal impairment, uncontrolled 
diabetes mellitus, malnutrition and hypothyroidism (43).
Visual deficit, especially bitemporal hemianopia due 
to compression of the optic chiasm, can also occur (35). 
Thus, it is mandatory to perform visual field perimetry, 
preferably the Goldmann method, in all patients with 
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adenoma is very close (< 1 mm) or compresses the 
optic chiasm. Confrontational visual field performed 
by the endocrinologist in the outpatient clinic may not 
be precise whenever visual field perimetry is indicated. 
Thus, a formal visual field perimetry is needed. 
In the analysis of sellar region imaging, preferably by 
MRI, it is important that an experienced neuroradiologist 
is on the team to set the adenoma size (microadenoma 
vs. macroadenoma); evaluate if there is extrasellar 
extension of the tumor, optic chiasm compression and/
or sellar floor erosion (in this case, CT view is better 
to view erosion of the sellar floor); as well as aid in the 
differential diagnosis of masses that can affect the sellar 
region. MRI at diagnosis can already provide evidence 
of aggressive tumors, such as voluminous adenomas 
with an important extrasellar component, compression 
of adjacent structures and bone destruction. Pituitary 
adenomas usually present hypo- or isointense compared 
to normal pituitary tissue in T1 images on MRI. After 
administration of gadolinium, adenomas often present 
low contrast uptake, while the contrast enhancement in 
normal pituitary tissue occurs earlier (44). 
Several other pathologies may be the cause of sellar 
mass and must be considered in the differential diagnosis 
(Table 3), although this distinction is difficult in many 
cases because the clinical presentations and radiological 
aspects may be similar (45,46). In this scenario, the role 
of the experienced neuroradiologist is crucial in the 
differential diagnosis of sellar masses. In other cases, 
some clinical, endocrinal and radiological findings of 
patients with a non-pituitary sellar or parasellar mass are 
present and help in this differentiation [for details on the 
other sellar lesions, see reference #(47)]. The correct 
etiologic diagnosis is important because the treatment 
of choice for many of these sellar and parasellar masses 
differs from that of pituitary adenomas.    
The presence of diabetes insipidus (DI) is common 
in tumors of non-pituitary origin and indicates that the 
sellar mass is most likely not a pituitary adenoma (45). 
Likewise, it is unlikely to diagnose a tumor that reduces 
light of the internal carotid artery by the cavernous 
sinus invasion as a pituitary adenoma (48). The dosage 
of the α subunit of the glycoprotein hormones can aid 
in the differential diagnosis, but it is elevated in only 
30% of NFPA patients (15). Thus, high levels of α 
subunit indicate pituitary origin of mass, but normal 
values do not rule out NFPA as an etiologic diagnosis. 
Importantly, the α subunit is high in physiological 
situations such as menopause and pregnancy.
The definitive diagnosis of NFPA and the definition 
of its subtype are performed by histopathological analysis 
of the surgical specimen (12,49). Thus, patients not 
undergoing surgery remain with a presumptive diagnosis 
of NFPA. It is important to remember that approximately 
90% of sellar masses are pituitary adenomas, and only 
10% are lesions of non-pituitary origin, most of which 
are craniopharyngiomas and Rathke’s cleft cysts (50). 
Thus, a histopathological exam is needed to confirm 
pituitary adenoma; whenever possible, IHC should be 
performed for pituitary hormones, Ki-67, a marker of 
cell proliferation, and protein p53.
The summary for NFPA diagnoses is shown in Chart 2 
and for requesting additional tests at diagnosis in Chart 3.
Table 3. Differential diagnosis of major lesions that affect the sellar region
Pituitary tumors
• Prolactin-secreting pituitary adenoma
• Clinically nonfunctioning adenoma
• Growth hormone-secreting pituitary adenoma (acromegaly)
• Corticotropin-secreting pituitary adenoma (Cushing’s disease)









• Metastasis (mainly: breast, lung and kidney)
Cysts
• Cyst of Rathke’s pouch
• Arachnoid cyst
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Chart 2. Summary for the diagnosis of clinically nonfunctioning pituitary 
adenoma
• Hormone hypersecretion evaluation should be based on laboratory test 
analysis through IGF-I and prolactin
• Special attention should be given to interpretation of plasma prolactin 
values because normal or slightly elevated values (hook effect) may occur 
in the macroprolactinomas, especially those > 3 cm, as well as prolactin 
levels until 150-200 ng/mL (hypothalamic-pituitary disconnection) can be 
seen in patients with NFPA. Thus, a new dosage after a prolactin serum 
dilution of 1:100 is mandatory to distinguish prolactinoma from a NFPA 
• Hypercortisolism evaluation should be based on laboratory test analysis 
only in cases of clinical suspicion of Cushing’s syndrome
• Imaging exams of the sella turcica, preferably by MRI, to assess lesion 
size and its relationship with adjacent structures as well as assist in 
differential diagnosis with other sellar masses. In this context, the 
participation of an experienced neuroradiologist is essential
• In patents submitted to surgery, histopathological exam is needed to 
confirm pituitary adenoma
IGF-I: insulin-like growth factor type I; NFPA: nonfunctioning pituitary adenoma; MRI: magnetic 
resonance imaging.
Chart 3. Summary to request additional tests at diagnosis of clinically 
nonfunctioning pituitary adenoma
• Visual field perimetry, preferably Goldmann method, in patients with 
macroadenomas with suprasellar expansion that reach the optic chiasm
• The assessment of pituitary function must be performed in patients with 
lesions > 6 mm through dosages of cortisol, free T4, IGF-I, prolactin, LH, 
FSH, and in men, testosterone. In women, the determination of 
gonadotropin levels and menstrual cycles is sufficient for the evaluation of 
gonadal function
T4: thyroxin; IGF-I: insulin-like growth factor type I; FSH: follicle stimulating hormone; LH: 
luteinizing hormone; TSH: thyroid stimulating hormone.
TREATMENT
In most cases, the treatment of NFPA patients requires 
a multidisciplinary approach involving the participation 
of endocrinologists, neurosurgeons, neuroradiologists, 
neuropathologists and radiation therapists. The 
established therapeutic approaches for patients with 
NFPA include observation (clinical follow-up), surgery 
and radiotherapy (RT).
In general, the main objectives of treatment of 
patients with macroadenomas are the preservation or 
restoration of visual and pituitary functions and long-
term control of tumor growth.
Surgery
The principal objective is decompression of the optical 
pathways and the preservation of adjacent structures as 
well as normal pituitary tissue. The success of surgical 
treatment varies directly with the surgeon’s experience 
and skill and inversely with the largest tumor diameter, its 
consistency, adhesion and degree of invasion (27,51-52). 
Experience is defined by the completion of at least 50 
transsphenoidal surgeries annually (53). Thus, surgery 
should be performed in specialized reference centers.
Total resection of the tumor may be curative, 
which occurs most frequently in those with little or 
no extrasellar extension (7). In fact, the presence of 
cavernous sinus invasion and largest tumor diameter 
were negative predictors of complete tumor resection 
in some series (25,27,54). The total resection rate is 
highly variable, from 20-83% (mean approximately 
50%), likely reflecting the advances in surgical and 
imaging techniques (particularly endoscopic technique) 
over time, as well as accumulated experience of 
neurosurgeons (25-28,33,55-58). Thus, about half of 
the patients are left with residual tumor after surgery. 
Transsphenoidal surgery is the treatment of choice 
for patients with neuro-ophthalmologic symptoms 
because it is the only treatment modality capable of 
immediately determining decompression of the optical 
pathways. Visual improvement can be observed in up to 
80% of patients (59). Thus, surgery should be indicated 
for patients with neuro-ophthalmologic complaints 
and/or tumors affecting the optic pathway. It is also 
indicated for patients with apoplexy who develop neuro-
ophthalmologic complaints. In these cases, surgery is 
urgent (Chart 4). Patients with clinical presentation of 
apoplexy who are not operated on within a few days 
should undergo new imaging examination, even in 
cases with persistent visual loss due to tumor necrosis.
Chart 4. Summary for surgery
• Should be performed in reference centers for pituitary surgery
• Should be performed in patients with neuro-ophthalmologic complaints 
and/or tumors affecting the optical pathways, except in patients at high 
risk for surgery or who refuse the procedure
• Should be performed with urgency in patients with apoplexy who present 
neuro-ophthalmologic complaints
The recovery of pituitary function occurs in 
30-50% of cases; however, recovery of adrenal and 
thyrotrophic function is more likely than somatotrophic 
or gonadotropic sectors (60). Losa and cols. (27) 
reported improvements in gonadal, thyroid and 
adrenal axes in 32.8%, 41.6% and 35.7%, respectively, 
and postsurgical worsening in 5.8%, 7.5% and 5.6% of 
patients, respectively. Nomikos and cols. (28) reported 
improvements in gonadal, thyroid and adrenal axes 
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and postsurgical worsening in 2.1%, 4.5% and 1.5% of 
patients, respectively.
The transsphenoidal approach is the main surgical 
pathway, which has a low mortality rate when 
performed by skilled neurosurgeons (27,61-63). 
Major complications are rare and include worsening 
of visual field (0.5-2.4%), cerebrospinal fluid leak (1.5-
4.2%), carotid artery lesion (0.4-1.4%), meningitis 
(0.5-1.9%) and hemorrhage (0.8-2.8%). Transitory 
diabetes insipidus can occur in up to 15% of surgeries, 
but its permanent form is less frequent (0.9-5%). The 
perioperative mortality rate is also low, ranging from 
0.2 to 1.2% (61,62,64,65).
Adequate replacement of corticotrophic and thyro-
trophic axes deficiencies before surgery is indicated, or 
at least, the glucocorticoid immediately before surgery 
in emergency cases to reduce surgical risk (66). The 
replacement should be kept in the postoperative period 
until further evaluation of all pituitary function is made.
Pituitary function and the visual field perimetry 
should be assessed 1-3 months after surgery and the 
treatment of hypopituitarism introduced according to 
hormone deficiencies. From the early postoperative 
period until the evaluation of pituitary function, special 
attention should be given to the corticotrophic axes 
for the risk of adrenal insufficiency. The assessment of 
pituitary function should be performed 1-3 months 
after surgery through dosages of cortisol, free T4, 
IGF-I, prolactin, LH, FSH, and in men, testosterone. 
In premenopausal women, determination of menstrual 
cycles is sufficient for the evaluation of gonadal function. 
The assessment of tumor resection extent should be 
made three months after surgery [three months is the 
minimum time for sellar MRI clearly showing a residual 
tumor, with less possibility of misinterpretation with 
postsurgical changes (surgical debris, for example)]. 
This MRI serves as the baseline imaging exam for 
comparison with the next MRI during follow-up 
(Chart 5).
Chart 5. Summary for outpatient postoperative evaluation
• Evaluation of pituitary function 1-3 months after the procedure - cortisol, 
free T4, IGF-I, prolactin, LH, FSH, and in men, testosterone. In 
premenopausal women, determination of menstrual cycles is sufficient to 
assess gonadal function
• Evaluation of the visual field through visual perimetry one month after 
surgery in patients who present initially with visual field defect
• Imaging exam of the sellar region, preferably MRI, at least 3 months after 
surgery
T4: thyroxin; IGF-I: insulin-like growth factor type I; FSH: follicle stimulating hormone; 
LH: luteinizing hormone; TSH: thyroid stimulating hormone; MRI: magnetic resonance imaging.
The long-term follow-up of patients undergoing 
surgery, but without receiving any type of adjuvant 
treat ment, is detailed ahead.
Radiotherapy
RT has been used as complementary treatment 
(adjuvant) to surgery to reduce the risk of tumor 
regrowth (67). Two modalities of RT are available, 
conventional and stereotactic, which can be fractionated 
or in single dose (radiosurgery).
Conventional RT is administered in fractionated 
doses four to five times a week for four weeks. There is 
no doubt of the effectiveness of RT in tumor control. 
Several studies have evaluated the impact of adjuvant 
conventional RT on tumor recurrence, and the 
progression-free rate is higher than 90% even in series 
with long-term follow-up (approximately 20 years) 
(68-71).
However, despite its effectiveness, there is 
no consensus on the systematic use of RT in the 
postoperative period in patients who remain with 
residual tumor. Nonetheless, the regrowth frequency 
is relatively high, occurring in approximately 40-50% 
of patients with residual tumor on imaging exams 
(26,33,54,56,71,72), with slow growth that is often 
insufficient to determine clinical manifestation (73). 
For some authors, if the remaining tumor is small and 
its evolution can be followed through periodic imaging 
exams (expectant approach), RT is only indicated when 
there is evidence of significant tumor growth (74). A 
recent meta-analysis showed that the tumor doubling 
time was 3.4 years, which means that in most adenomas, 
regrowth of residual tumor is a slow process and thus 
may not achieve sufficient dimensions to determine 
compressive symptoms (73). Furthermore, in 50-60% 
of cases, no growth is presented during follow-up (73).
To date, there are no markers to identify which 
tumors will present regrowth after surgery, making 
it difficult to decide which patients should undergo 
irradiation (75,76). Thus, indication for RT should be 
individualized, taking into account such issues as tumor 
characteristics on MRI at diagnosis, age, tumor doubling 
time, pituitary function, and fertility because the risk of 
hypopituitarism due to radiotherapy is high and grows 
over time with follow-up. In general, RT is reserved 
for cases of tumors not completely resected by surgery 
and that present progressive tumor growth during 



















Diagnosis and treatment of clinically nonfunctioning pituitary adenoma
Arch Endocrinol Metab. 2016;60/4
patients who, at diagnosis, already present aggressive 
tumors (large adenomas with invasion and compromise 
to structures adjacent to sellar region) and/or tumors 
with pathologic characteristics that demonstrate 
aggressiveness, such as high mitotic index, Ki-67 > 
3% and extensive immunostaining for p53 (atypical 
adenomas according to the classification of the 2004 
World Health Organization) (49), and possibly silent 
corticotropinoma (77,78). Additionally, RT should 
be indicated in cases of persistent residual tumor after 
second surgery performed due to tumor recurrence. 
Finally, it can be used as primary therapy for patients 
with tumors proximate or reaching the optic pathway 
and concurrently present high surgical risk or surgery 
refusal (Chart 6). In this context, radiosurgery was 
effective in controlling tumor growth in 85% of patients 
in 10 years of follow-up (79). Patients undergoing RT 
should be monitored by MRI annually in the first five 
years and then every 2-3 years.
Chart 6. Summary for radiation therapy and monitoring
• Tumors that present progressive growth during follow-up
• Aggressive tumors on MRI at diagnosis and/or tumors with pathological 
characteristics that show aggressiveness
• Persistent residual tumor after second surgery for relapsing disease
• Primary therapy for patients with proximate tumors or that reach the optic 
pathways and high concomitant surgical risk or patient refusal for surgery
• Evaluation of hypopituitarism every 6 months
• Annual sellar MRI during the first five years and then every 2-3 years
MRI: magnetic resonance imaging.
Littley and cols. (80) evaluated 165 patients 
undergoing conventional RT; after five years 
of treatment, the incidence of GH deficiency, 
gonadotropin (LH and FSH), ACTH and TSH was 
100%, 91% 77% and 42%, respectively. While observing 
different sensitivities between pituitary cells, the 
deficiency state can be unpredictable, which means 
the regular assessment of complete pituitary function 
in patients undergoing RT should be every 6 months. 
In addition, new deficiencies may appear up to 20 
years after, justifying long-term follow-up of pituitary 
function (68). Evaluation for hypopituitarism should 
be performed every 6 months after RT in patients who 
have total or partial pituitary function preserved.
In addition to damage to the pituitary, there is a 
risk of optic neuropathy, especially to the optic chiasm 
(81), neurocognitive dysfunction (82), and more 
rarely, possible induction of other tumors of the central 
nervous system, especially meningiomas, astrocytomas 
and gliomas (83). It is important to consider that these 
complications occurred at times when the treatment 
was carried out with dated techniques, and risk has not 
yet been fully established with new RT techniques. In 
addition to the above side effects, studies have evaluated 
the relationship between RT with increased mortality, 
especially for cerebrovascular disease (84,85). Brada 
and cols. (85) found a relationship between radiation 
dose and the risk of cerebral infarction in a study with 
331 patients. The relative risk of occurrence of a first 
stroke in relation to the general population was 4.1 
in this study. Furthermore, hypopituitarism, as well as 
hormone replacement, is also related to cerebrovascular 
disease and increased mortality (86,87). Thus, increased 
mortality from cerebrovascular disease appears to be 
multifactorial, involving the direct effect of radiation 
on cerebral vessels, hypopituitarism and its treatment 
(88). Because risk of cerebrovascular disease is a long-
term effect, the radiation used in the reported cases 
was from an older technique, where parts of the brain 
received up to half or a third of the total dose.
In an attempt to minimize the risks of RT, a 
stereotactic method was developed. This technique has 
successfully replaced conventional RT in controlling 
the growth of tumor remnants (89). In the study of 
Mingione and cols. (90), 59 of 90 patients (65.6%) 
with NFPA treated after surgery showed tumor volume 
reduction, the tumor remained stable in 24 (26.7%) 
and there was tumor growth in 7 cases (7.8%). Like 
conventional RT, the rate of tumor control of NFPA 
with stereotactic RT published in different series is above 
90%, but with less follow-up (91). Mokry and cols. (92) 
reported an incidence of hypopituitarism of 20%, but it 
may have been underestimated by the follow-up time 
(28.9 ± 21.5 months) (93). In the series of Hoybye and 
cols. (94), hypopituitarism developed in 68% of patients 
with corticotropinoma at a mean follow-up of 17 years 
(12-22 years). As there is lesser existing experience with 
stereotactic irradiation in single or fractionated doses, 
more long-term studies are needed to assess the actual 
incidence of side effects, such as hypopituitarism, optic 
neuropathy, neurocognitive dysfunction, cerebrovascular 
disease, possible induction of other tumors of the central 
nervous system, and mortality (93).
Medications
NFPA are tumors without an established drug 
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for the treatment of NFPA: dopamine agonists (DA), 
somatostatin analogs (SA) and gonadotropin-releasing 
hormone (GnRH) analogues (95). Temozolomide 
has also been used in some centers for patients with 
aggressive tumors. However, to date, none of these are 
routinely used or formally indicated for the treatment of 
these tumors.
A – Dopamine agonists 
DA was the first class of drugs used in the treatment 
of prolactinomas and somatotropinomas; bromocriptine 
(BRC) and cabergoline (CAB) are both commercially 
available DA in Brazil. These drugs act directly on the 
dopamine receptor type 2 (DR2), present in normal 
pituitary (96) and pituitary adenoma (96,97). The use 
of this class of drugs in the treatment of NFPA is based 
on the observation that these tumors express DR2 
(96,98,99). Promising results have been reported on the 
efficacy of CAB in the control of tumor growth (98,99). 
Pivonello and cols. (98) sought to correlate DR2 
expression with the effect of CAB on tumor volume 
in patients with NFPA. The study included 18 patients 
undergoing surgical treatment, of which 9 (50%) 
remained with residual tumor and were treated with 
CAB for a period of 1 year. Significant tumor reduction 
(over 25%) was observed in 56% of patients. Among 
them, remarkable tumor reduction (greater than 50% 
of the initial volume) was identified in two patients, 
and moderate tumor reduction (25-50% of the initial 
volume) was observed in three patients. All patients 
with significant reduction of adenoma expressed DR2. 
A similar result was found by Vieira Neto and cols. 
(99), who observed tumor reduction of > 25% in 67% 
(6/9 patients) after 6 months of treatment with CAB. 
In both studies, the cabergoline dose was titered up to 
3 mg/week or to the highest tolerated dose.  
Greenman and cols. (100) evaluated the use of DA 
immediately after surgery or after detection of remnant 
tumor growth during follow-up. Thirty-three patients 
received DA during a mean period of 40 months and 
were matched with a group of 47 patients who were 
not treated with the drug. Tumor reduction or stability 
was observed in 18 of 20 patients (90%), when DA 
was started immediately after detection of the residual 
tumor on postoperative MRI. In 13 patients, treatment 
was started only after detection of remnant tumor 
growth during routine visits. In this group, reduction 
or stabilization of the tumor was detected in 8 of 13 
patients (61.5%). Conversely, tumor size remained stable 
in only 18 of 47 patients (38.3%) not treated with DA, 
and tumor growth was detected in 29 patients (61.7%). 
Thus, based on these results, the authors concluded 
that DA treatment induces a reduction or stabilization 
of tumor volume, particularly when the treatment was 
initiated prior to detection of tumor relapse/regrowth.
Although CAB has not been included in the treatment 
algorithm of patients with NFPA, a therapeutic attempt 
can be made according to the clinical judgment in 
individual cases with postoperative residual tumor, 
especially those with extrasellar extension (regrowth 
predictor). In these patients, small growths may be 
clinically relevant in terms of compressive effects. 
In this context, CAB could be attempted before RT 
indication for control of tumor regrowth, avoiding the 
side effects related to radiation, especially in patients 
with preserved pituitary function.
The initial dose can be 0.5 mg weekly, increasing 0.5 
mg each week until a maximum dose of 3.0 mg/week. 
If the patient has intolerance during titration, use the 
highest tolerated dose. The effectiveness of CAB should 
be assessed by MRI, which can be performed after 6 
months of medication at a maximum/tolerated dose. 
It is not defined in the literature what is considered a 
response to CAB, given the heterogeneity of the studies 
evaluating its effect on tumor volume. Tumor stability 
may be considered a positive response; however, as 
mentioned above, 50-60% of patients will keep tumor 
stability even without treatment. Therefore, in cases 
with stability, it is not possible to infer the actual effect 
of the treatment, and individual analysis of cost/
benefit should be made to decide the maintenance of 
medication in these cases. Similarly, there is no data on 
the withdrawal of CAB among patients who present a 
benefit from its use. According to the clinical judgment 
of the physician, if the patient has a benefit and no side 
effects, the drug can be maintained indefinitely. While 
using CAB, after the initial 6-month assessment of 
the use of the maximum/tolerated dose, MRI should 
be made annually. Because the impact of CAB on 
tumor volume is uncertain, and pituitary function may 
deteriorate due to tumor growth, pituitary function 
should be assessed regularly every 6-12 months for 
safety reasons. If the tumor presents progressive growth 
during the use of CAB, RT should be indicated. If 
the patient develops visual impairment or the tumor 
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In most studies, BRC has failed to induce tumor 
shrinkage (101-103). The compilation of data from 
seven studies on the effectiveness of BRC in the 
treatment of 84 patients with NFPA has shown no 
reduction in tumor volume in 76 patients (90%) and 
tumor increase in one case (1.2%) (101). In seven 
patients (8%), a small tumor reduction was observed, 
although one case evolved coincident with pituitary 
apoplexy. Visual deterioration was observed in five 
patients (6.6%), whereas only one patient showed 
improvement of the visual field (101).
Adverse reactions to CAB occurred in 13% of 
patients in a large series in which this drug was given 
(104) and included nausea, dizziness, headache, 
constipation, dry mouth, nasal obstruction and 
postural hypotension (105). Schade and cols. (106) 
showed a high risk of heart valve lesion in patients with 
Parkinson’s disease using CAB in doses much higher 
than those used for pituitary adenomas. These authors 
showed that this risk was dose- and time-dependent. 
Although clinically relevant valve lesion has not been 
reported in patients taking DA to treat prolactinomas 
(107), a transthoracic echocardiography should be 
performed as good clinical practice before CAB and 
then every 12 months during therapy in patients taking 
CAB at a dose > 2.0 mg/week (34,108). The drug 
should be discontinued if there is evidence of onset or 
progression of valve lesion.
B – Somatostatin analogues
SA exerts its pharmacological properties through SSTR, 
with five subtypes having been identified in humans 
(SSTR1, 2, 3, 4 and 5) and present in normal pituitary 
and pituitary adenoma (96,109-111).
The synthetic SA currently available in clinical 
practice, octreotide (OCT) and lanreotide (LAN), exert 
their action primarily by binding to SSTR subtypes 2 
and 5 (112). The SSTR detection in NFPA raised the 
possibility that SA might be used in the treatment of 
this tumor type (109,113,114). However, the favorable 
effects of therapy with commercially available SA have 
been variable and infrequent, beyond correlating 
poorly with SSTR expression (115). Vieira Neto and 
cols. (114) observed that the most expressed receptor 
among NFPA was SSTR3, while SSTR2 expression was 
found to be low, which could explain the low efficacy 
of SA. Thus, we do not recommend these SA for the 
treatment of patients with NFPA. 
New SA with potential therapeutic impact on the 
management of patients with pituitary adenomas are 
under study. Pasireotide is a universal SA with action on 
SSTR subtypes 1, 2, 3 and 5. As pasireotide has action 
on SSTR3, the most expressed receptor in NFPA, it 
is possible that this drug could be an effective option 
in the therapeutic approach for NFPA patients. Studies 
evaluating its in vivo effect on tumor volume in patients 
with NFPA are under evaluation (Figure 1).
C – GnRH analogues
This class of drugs acts through receptors for GnRH, 
exerting their effects by saturation of these receptors 
in the gonadotropic cells, thereby reducing hormone 
production. Because some NFPAs are positive for 
gonadotropins, GnRH agonists and antagonists have 
been tested in the treatment of these adenomas. 
However, the use of GnRH agonist analogues had a 
null effect or exacerbated gonadotropin secretion with 
no change in tumor dimensions (10,116-118).
Thus, GnRH analogues are not recommended 
as medical therapy for NFPA because it does not 
provide tumor reduction and can eventually exacerbate 
hormone hypersecretion or even cause pituitary 
apoplexy, especially in large volume tumors (119).
D – Temozolomide
Temozolomide is an alkylating agent routinely used 
in the treatment of brain gliomas and metastatic 
melanomas that has a cytotoxic effect. It also acts 
by inhibiting angiogenesis in tumor tissues through 
an unknown mechanism. O6-methylguanine DNA 
methyltransferase (MGMT) is an enzyme that repairs 
DNA by removing the alkyl group and inducing 
resistance to temozolomide (120,121). Widhalm 
and cols. (121) showed that, in aggressive NFPA, 
low MGMT immunoreactivity was found in 50% of 
patients compared with 24% of patients with non-
aggressive NFPA, suggesting that temozolomide may 
be a therapeutic option in those patients. The main 
side effect of the drug is the induction of lymphopenia 
(120). Treatment with temozolomide can be attempted 
in patients with aggressive tumors that did not achieve 
control of tumor growth despite RT and other 




















Diagnosis and treatment of clinically nonfunctioning pituitary adenoma










NFPA: nonfunctioning pituitary adenoma; MRI: magnetic resonance imaging; CAB: cabergoline; RT: radiotherapy.
* For cases that can be followed up with MRI, are asymptomatic from a visual point of view and the tumor is located far from the optical pathways, there is no need for visual field perimetry.
1 For asymptomatic patients with no compression of the optic pathway but with tumors near the optic chiasm, the decision between surgery and follow-up should be individualized, taking into 
consideration issues such as age, fertility/pregnancy, pituitary function and the patient’s desire.
2 RT can be used as primary therapy for patients with tumors near or that reach the optic pathways and present surgical risk high enough to contraindicate surgery.
3 Tumors with pathologic features of aggressiveness are those with a high mitotic index, Ki-67 > 3% and extensive immunostaining for p53.
Figure 1. Management of patients with clinically nonfunctioning pituitary adenoma
NFPA
Macroadenoma
Visual field impairment and/or  
compression of optic pathways
Yes No
Surgery Follow-up with MRI, pituitary function visual field perimetry*
MRI 3 months after 
surgery
No residual tumor Small intrasellar  
residual tumor
Follow-up with MRI and 
pituitary function




Residual tumor with 
extrasellar extension
Aggressive tumor at 
diagnosis and/or residual 
tumor with aggressive 
pathological 
characteristics
Evident tumor growth 
with visual impairment 
and/or compression of 
optic pathways
Progressive tumor growth 
without visual impairment  
and without compression of 
optic pathways
Surgery if there is evident tumor growth and/or development of visual field  





LONG-TERM FOLLOW-UP OF PATIENTS 
UNDERGOING SURGERY 
Postoperative follow-up of patients with no residual 
tumor
For patients with postoperative MRI with no evidence of 
residual tumor, the course of treatment must be clinical 
follow-up, with no need for adjuvant treatment, such 
as RT because recurrence occurs in approximately 10% 
of cases (26,33,54,56,72) (Chart 7). In fact, the meta-
analysis performed by Chen and cols. (73) to evaluate 
recurrence after surgery found a recurrence rate of 12% 
(371 patients), with a progression-free survival rate of 
96% and 82% at 5 and 10 years, respectively.
Chart 7. Postoperative follow-up of patients with no residual tumor
• The best approach is clinical follow-up
• Annual MRI in the first 5 years. In the absence of relapse during this 
period, MRI every 2-3 years
• Visual field perimetry should be performed only in patients who present 
tumor growth about to reach the optical pathway and/or determine visual 
impairment
• Evaluation of pituitary function should be performed every 6-12 months if 
MRI does not demonstrate relapse. If there is recurrence, evaluation of 
pituitary function should be performed at the time of detection
MRI: magnetic resonance imaging; RT: radiotherapy.
Follow-up for these patients should be performed 
with annual MRI in the first 5 years. In the absence of 
relapse during this period, MRI should be performed 
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should be individualized. If growth is not clinically 
relevant and the patient remains asymptomatic, a new 
MRI should be performed in 6 months to detect if the 
tumor is in progressive growth. If this is the case and 
the patient does not have compressive complaints, RT 
is indicated. If the patient develops visual impairment 
or the tumor begins to compress visual pathways, 
further surgery is indicated.
Laboratory evaluation for hypopituitarism during 
follow-up should be performed every 6-12 months if 
MRI does not show recurrence. Laboratory evaluation 
for hypopituitarism should be performed during 
follow-up every 6-12 months because new deficiencies 
may reflect tumor growth/recurrence. To avoid much 
expenditure for the patient and the hospital, annual MRI 
scans might be combined with semi-annual laboratory 
evaluation because the intermediate blood tests could 
provide a way to detect new deficiencies before the next 
scheduled MRI scan. If there is recurrence, evaluation 
of pituitary function should be performed at the time 
of detection.
Visual field perimetry should be performed only in 
patients who present tumor growth about to reach the 
optical pathway and/or determine visual impairment. 
For patients who can be followed with MRI and are 
asymptomatic from a visual point of view, there is no 
need for regular visual perimetry.
Postoperative follow-up of patients with residual 
tumor
As mentioned above, approximately half of patients with 
NFPA have residual tumor after surgery (25-28,33,55-
58). For these patients, there is no consensus on the 
best approach. RT is highly effective in preventing 
tumor regrowth, but it is associated with significant 
long-term complications. Conversely, postponing 
any type of treatment is associated with progression 
(tumor regrowth) in approximately 40-50% of cases 
(26,33,54,56,71,72,122). Chen and cols. (73) showed 
that there was tumor regrowth in 46% of 600 patients 
with tumor remnants, with a progression-free survival 
rate of 56% and 40% at 5 and 10 years, respectively.
To date, there is no reliable marker to predict tumor 
regrowth after surgery. Pathological characteristics have 
been studied with the aim of analyzing the biological 
behavior of NFPA. In this scenario, IHC for Ki-67, a 
marker of cell proliferation, and p53 protein remains 
the most widely used (75). Although some studies have 
found a higher rate of Ki-67 labeling in invasive tumors 
(123-125), this result has not been replicated by others 
(18,126). Studies that evaluated the predictive value of 
the Ki-67 index for recurrence or regrowth of residual 
tumor were also inconsistent (76,127-131). The lack 
of unanimity between studies can be explained in part 
by the fact that the Ki-67 quantifies only the replication 
potential of the tumor and does not assess tumor growth, 
which results from the balance between proliferation 
and cell death (132). In general, high Ki-67 (> 3%) 
suggests a more aggressive tumor, whereas tumors with 
low Ki-67 (< 3%) may or may not exhibit aggressive 
behavior. Similarly, extensive immunostaining for p53 
suggests a more aggressive tumor, whereas tumors 
that are IHC-negative for p53 may or may not exhibit 
aggressive behavior (125). Finally, pluri-hormone 
adenomas also appear to present a higher chance of 
recurrence or relapse (133), and silent corticotroph 
adenomas may also have more aggressive behavior 
(77,78).
Several large series evaluating postoperative 
recurrence/tumor regrowth have shown that the 
presence of residual tumor and/or follow-up duration 
appear to be the two major determinants of recurrence/
regrowth (26,33,54,56,71,72). Dekkers and cols. (33) 
found that, among patients without residual tumor, 
the recurrence-free rate at 5 and 10 years was 100%. 
In patients with residual tumor, after a mean follow-
up of 6.3 years (3-11 years), the progression-free 
rate at 5 and 10 years was 92% and 74%, respectively. 
In this study, follow-up time was a tumor regrowth 
predictor (33). In the series by O’Sullivan and cols. 
(56) the relapse rate among patients without residual 
tumor was 0% and 33.5% for those with residual 
tumor during median follow-up of 4.1 years (1-20.7 
years), so the rate of progression at 5 and 10 years was 
24.4% and 51.5%, respectively. In this study, follow-
up duration and the presence of residual tumor with 
extrasellar extension [odds ratio (OR) 3.73] were 
predictors of regrowth (56). Greenman and cols. (54) 
similarly found that the presence of residual tumor 
and supra- and infrasellar extension were associated 
with an increased risk of regrowth. Thus, to date, it 
seems reasonable to use the presence of residual tumor 
after a successful surgery to select high-risk patients 
for possible medical intervention, leaving the low-
risk patients (without residual tumor) under close 
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For patients with small residues (intrasellar) far 
from the optic chiasm, clinical follow-up (“wait and 
see policy”) seems to be the best approach since 
growth, when it occurs, is slow and insufficient to 
determine compressive symptoms (73). Follow-
up should be performed with an annual MRI in the 
first 5 years. In the absence of regrowth during this 
period, MRI should be performed every 2-3 years. 
Importantly, comparisons should be made between 
the current image exam and the previous exam as 
well as all previous exams, as small growths cannot 
be detected by comparing only the last two imaging 
exams. If regrowth is detected, the approach should 
be individualized. If growth is not clinically relevant 
and the patient remains asymptomatic, with the 
tumor still far from the optical pathways, a new 
MRI should be performed in 6 months to detect if 
the tumor is in progressive growth. If the tumor 
growth is in progression but the patient is 
asymptomatic, RT should be considered. In this 
context, CAB may also be an option provided the 
risks and benefits are discussed with the patient. 
Greenman and cols. (100) offered DA therapy in a 
subset of patients with NFPA (n = 13) upon tumor 
expansion. DA therapy ceased tumor growth in six 
patients (46.1%) and determined tumor reduction in 
two patients (15.4%). Tumor growth persisted in five 
patients (38.5%) despite therapy. Thus, the overall 
control rate was 61.5% (8/13). On the other hand, 
in untreated control patients, tumor size remained 
stable in only 38.3% (18/47), whereas tumor growth 
was verified in 29 controls (61.7%). Moreover, in the 
control group there was no case of spontaneous tumor 
reduction. Therefore, the authors concluded that DA 
therapy induces a reduction or stabilization of tumor 
volume in patients with tumor relapse/regrowth. 
Based on these results, CAB could be attempted 
before RT indication for control of tumor regrowth, 
avoiding the side effects related to radiation, especially 
in patients with preserved pituitary function.
 If treatment with CAB is introduced, MRI should 
be performed at 6 months to indicate whether there 
was stabilization/reduction of the lesion (which would 
justify the maintenance of medication) or tumor 
progression (which would indicate RT). If the patient 
develops visual impairment or the tumor begins to 
compress visual pathways, further surgery is indicated 
(Chart 8).
Chart 8. Postoperative follow-up of patients with residual tumor
• Patients with small residues (intrasellar) far from the optic chiasm should 
be submitted to clinical follow-up (“wait and see policy”)
• The follow-up should be with annual MRI in the first 5 years. In the 
absence of regrowth during this period, MRI every 2-3 years
• If regrowth is detected, the approach should be individualized
• If growth is not clinically relevant and the patient remains asymptomatic 
with the tumor still far from the optical pathways, a new MRI should be 
performed in 6 months to detect whether the tumor is in progressive 
growth
• If the tumor growth is in progression but the patient is asymptomatic, RT 
should be considered. CAB can also be an option
• If the patient develops visual impairment or the tumor begins to compress 
visual pathways, further surgery is indicated
• Evaluation of pituitary function every 6-12 months. For patients submitted 
to RT, evaluation of pituitary function should be performed every 6 months
• Annual visual field perimetry should be performed in patients with tumors 
with suprasellar extension or those whose tumor growth reaches the 
optical pathways and/or determines visual impairment
MRI: magnetic resonance imaging; RT: radiotherapy; CAB: cabergoline.
Laboratory evaluation for hypopituitarism during 
follow-up should be performed every 6-12 months. 
For patients submitted to RT, evaluation of pituitary 
function should be performed every 6 months.
Annual visual field perimetry should be performed 
in patients with tumors with suprasellar extension or 
those whose tumor growth reaches the optical pa-
thways and/or determine visual impairment.
Disclosure: no potential conflict of interest relevant to this article 
was reported.
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